

---

## Product Data Sheet

---

Product Name: PF-CBP1 hydrochloride

Cat. No.: GC36887

**Chemical Properties**

Cas. No. 2070014-93-4

SMILES CCCOC1=CC=C(CCC2=NC3=CC(C4=C(C)ON=C4C)=CC=C3N2CCN5CCOCC5)C=C1.Cl[H]Formula C<sub>29</sub>H<sub>37</sub>ClN<sub>4</sub>O<sub>3</sub>

M.Wt 525.08

Solubility DMSO: 100 mg/mL (190.45 mM); Water: < 0.1 mg/mL  
(insoluble)

Storage Store at -20°C

General For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the  
tips ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.Shipping Evaluation sample solution : ship with blue ice All other available size: ship with RT , or  
Condition blue ice upon request.Structure **Background**

CREB-binding protein (CBP) and E1A-associated protein p300 are transcriptional co-activators that modulate DNA replication, DNA repair, cell growth, transformation, and development.<sup>1,2</sup> Both CBP and p300 contain bromodomains, which mediate their binding to acetylated lysine residues on histones and other proteins.<sup>3</sup> PF-CBP1 is an inhibitor of the CBP and p300 bromodomains (IC<sub>50</sub>s = 125 and 363 nM, respectively).<sup>4</sup> It displays greater than 100-fold selectivity for the bromodomain of CBP over those of BRD4 and a panel of other proteins.<sup>4</sup> PF-CBP1 reduces the expression of inflammatory cytokines by LPS-stimulated primary macrophages.<sup>4</sup> It also suppresses the expression of RGS4 (regulator of G protein signaling 4) in primary cortical neurons.<sup>4</sup>

1. Iyer, N.G., Zdzienicka, H., and Caldas, C. p300/CBP and cancer. *Oncogene* 23(4):225-4231(2004)2. Kalkhoven, E. CBP and p300: HATs for different occasions. *Biochem. Pharmacol.* 68(1):145-1155(2004)3. Zeng, L., Zhang, Q., Gerona-Navarro, G., et al. Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP/p300. *Structure* 16(4):643-652(2008)4. Piatnitski Chekler, E.L., Pellegrino, J.A., Lanz, T.A., et al. Transcriptional profiling of a selective CREB binding protein bromodomain inhibitor highlights therapeutic opportunities. *Chem.**Biol.* 22(12):1588-1596(2015)**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA